CLAIMS:

1. A modified factor VII (FVII) polypeptide, comprising modifications in a FVII polypeptide, wherein:

the modifications are at positions corresponding to position 286 and position 298 in a FVII polypeptide having the sequence of amino acids set forth in SEQ ID NO:3 or in corresponding positions in a FVII polypeptide:

corresponding positions are identified by alignment with the polypeptide of SEQ ID NO:31 and

the modification at the position corresponding to position 286 is an amino acid replacement with an arginine (Arg, R);the modification at the position corresponding to position 298 is an amino acid replacement with a glutamine (Gln, Q); and

the modified FVII polypeptide exhibits increased coagulant activity compared to an unmodified FVII polypeptide that does not have the modifications at positions 286 and 298.

2. The modified FVII polypeptide of claim 1, wherein the modification at position 286 is replacement of Gln (Q) with Arg (R).

3. The modified FVII polypeptide of claim 1, wherein the modification at position 298 is replacement of Met (M) with Gln (Q).

4 The modified FVII polypeptide of claim 1, comprising the modifications Q286R and M298Q.

5. The modified FVII polypeptide of any of claims 1-4, wherein the unmodified FVII polypeptide comprises a sequence of amino acids set forth in any of SEQ ID NOS: 1-3, 18-74, 98, 158 or 343-353 or is a species variant thereof, or a variant having at least 95% sequence identity with the FVII of any of SEQ ID NOS: 1-3, 18-74, 98, 158 or 343-353, or is an active fragment of a FVII polypeptide that comprises a sequence of amino acids set forth in any of SEQ ID NOS: 1-3, 18-74, 98,158 or 343-353 or a variant having 95% sequence identity therewith .

6. The modified FVII polypeptide of any of claims 1-5, comprising one or more further modifications at another position in the FVII polypeptide.

7. The modified FVII polypeptide of claim 6, wherein a further modification is an amino acid replacement at a position corresponding to a position selected from among 51, 52, 54, 60, 66, 68, 109, 119, 122, 124, 130, 132, 158, 161, 175, 196, 197, 199, 202, 216, 222, 237, 239, 257, 286, 287, 290 292, 294, 296, 305, 314, 318, 321, 337, 341, 366, 373, 374, 394, 395 and 396.

8. The modified FVII polypeptide of claim 6, wherein a further amino acid modification is selected from among D196K, D196R, D196A, D196Y, D196F, D196W,

D196L, D196I, K197Y, K197A, K197E, K197D, K197L, K197M, K197I, K197V, K197F, K197W, K199A, K199D, K199E, G237W, G237T, G237I, G237V, T239A, R290A, R290E, R290D, R290N, R290Q, R290K, R290M, R290V, K341E, K341R, K341Q, K341N, K341M, K341D, G237T238insA, G237T238insS, G237T238insV, G237T238insAS, G237T238insSA, D196K197insK, D196K197insR, D196K197insY, D196K197insW, D196K197insA, D196K197insM, K197I198insE, K197I198insY, K197I198insA, K197I198insS, T239S, T239N, T239Q, T239V, T239L, T239H, T239I, L287T, M298Q, P321K, P321E, P321Y, P321S, Q366D, Q366E, Q366N, Q366T, Q366S, Q366V, Q366I, Q366L, Q366M, H373D, H373E, H373S, H373L, H373I, H373F, H373A, K161S, K161A, K161V, H216S, H216A, H216K, H216R, S222A, S222K, S222V, S222N, S222E, S222D, H257A, H257S, Gla Swap FIX , {Gla Swap FIX/E40L}, {Gla Swap FIX/K43I}, {Gla Swap FIX/Q44S}, {Gla Swap FIX/M19K}, {Gla Swap FIX/M19K/E40L/K43I/Q44S}, Gla Swap FX , Gla Swap Prot C, Gla Swap Prot S, Gla Swap Thrombin, S52A, S60A, E394N, P395A, R396S, R202S, A292N, A294S, G318N, A175S, K109N, A122N, G124S, A51N, T130N, E132S, S52N, P54S, S119N, L121S, T128N, P129A, Q66N, Y68S, S103S111delinsQRLMEDICLPRWGCLWEDDF, H115S126delinsQRLMEDICLPRWGCLWEDDF, T128P134delinsQRLMEDICLPRWGCLWEDDF, S103S111delinsIEDICLPRWGCLWE, H115S126delinsIEDICLPRWGCLWE, T128P134delinsIEDICLPRWGCLWE, S103S111delinsDICLPRWGCLWED, H115S126delinsDICLPRWGCLWED, T128P134delinsDICLPRWGCLWED, P406insIEDICLPRWGCLW, P406insGGGSIEDICLPRWGCLW, P406insDICLPRWGCLWED, P406insGGGSDICLPRWGCLWED, S103S111delinsSFGRGDIRNV, H115S126delinsSFGRGDIRNV, T127P134delinsSFGRGDIRNV, P406insCSFGRGDIRNVC, P406insGGGSCSFGRGDIRNVC, V158T, V158D, L287Tand E296V.

9. The modified FVII polypeptide of any of claims 6-8, comprising modifications selected from among Q286R/M298Q/K341Q, Q286R/M298Q/K199E, Q286R/M298Q/Gla Swap FIX, S222A/H257A/Q286R/M158Q, Q286R/M298Q/Q366D, Q286R/M298Q/Q366N, Q286R/M298Q/H373F, {Gla Swap FIX/E40L}/Q286R/M298Q, {Gla Swap FIX/K43I}/Q286R/M298Q, {Gla Swap FIX/Q44S}/Q286R/M298Q, {Gla Swap FIX/M19K}/Q286R/M298Q, {Gla Swap FIX/M19K/E40L/K43I/Q44S}/Q286R/M298Q, T128N/P129A/Q286R/M298Q, V158D/Q286R/E296V/M298Q, Gla Swap FIX/T128N/P129A/Q286R/M298Q, T128N/P129A/S222A/H257A/Q286R/M298Q, T128N/P129A/Q286R/M298Q/H373F, S52A/S60A/Q286R/M298Q, Gla Swap FIX/S52A/S60A/Q286R/M298Q, S52A/S60A/S222A/H257A/Q286R/M298Q, S52A/S60A/Q286R/M298Q/H373F, T239V/Q286R/M298Q, S222A/T239V/H257A/Q286R/M298Q, Gla Swap FIX/T239V/Q286R/M298Q, T239V/Q286R/M298Q/H373F, T239I/Q286R/M298Q, S222A/T239I/H257A/Q286R/M298Q, Gla Swap FIX/T239I/Q286R/M298Q, T239I/Q286R/M298Q/H373F, Gla Swap FIX/S222A/Q286R/M298Q, Gla Swap FIX/S222A/Q286R/M298Q/H373F, V158D/Q286R/E296V/M298Q/H373F, H257A/Q286R/M298Q, H257S/Q286R/M298Q, S222A/H257S/Q286R/M298Q, H257S/Q286R/M298Q/H373F, S222A/Q286R/M298Q/H373F, S222A/Q286R/M298Q, T128N/P129A/A175S/Q286R/M298Q, A122N/G124S/A175S/Q286R/M298Q, T128N/P129A/A175S/S222A/H257A/Q286R/M298Q, A122N/G124S/A175S/S222A/H257A/Q286R/M298Q, T128N/P129A/A175S/Q286R/M298Q/H373F,

A122N/G124S/A175S/Q286R/M298Q/H373F, {Gla Swap FIX /K43I}/T128N/P129A/Q286R/M298Q, T128N/P129A/Q286R/M298Q/Q366N, {Gla Swap FIX /K43I}/Q286R/M298Q/Q366N, {Gla Swap FIX /K43I}/ T128N/P129A/Q286R/M298Q/Q366N, V158D/Q286R/E296V/M298Q, T128N/P129A/Q286R/M298Q/Q366N/H373F, T239V/Q286R/M298Q/Q366N, T239I/Q286R/M298Q/Q366N, T128N/P129A/T239V/Q286R/M298Q, T128N/P129A/S222A/T239V/H257A/Q286R/M298Q, T128N/P129A/T239V/Q286R/M298Q/H373F, T128N/P129A/T239I/Q286R/M298Q and T128N/P129A/T239I/Q286R/M298Q/H373F.

10. The modified FVII polypeptide of any of claims 6-9, comprising modifications selected from among T128N/P129A/Q286R/M298Q, T239I/Q286R/M298Q/Q366N, T239V/Q286R/M298Q/Q366N, T128N/P129A/Q286R/M298Q/Q366N/H373F, V158D/Q286R/E296V/M298Q/H373F, A122N/G124S/A175S/Q286R/M298Q/H373F, T128N/P129A/A175S/Q286R/M298Q/H373F, A122N/G124S/A175S/S222A/H257A/ Q286R/M298Q, T128N/P129A/A175S/S222A/H257A/Q286R/M298Q, A122N/G124S/ A175S/Q286R/M298Q, T128N/P129A/A175S/Q286R/M298Q, H257A/Q286R/M298Q, Gla Swap FIX/S222A/Q286R/M298Q, S222A/Q286R/M298Q, Gla Swap FIX/ S222A/Q286R/M298Q/H373F, S222A/Q286R/M298Q/H373F, S222A/H257S/Q286R/M298Q, T239I/Q286R/M298Q/H373F, S222A/T239I/H257A/Q286R/M298Q, T128N/P129A/T239I/Q286R/M298Q, Gla Swap FIX / T239I/Q286R/M298Q, T239I/Q286R/M298Q, T128N/P129A/S222A/T239V/H257A/Q286R/M298Q, S222A/T239V/H257A/Q286R/M298Q, T128N/P129A/T239V/Q286R/M298Q, Gla Swap FIX/T239V/Q286R/M298Q, V158D/Q286R/E296V/M298Q, T128N/P129A/Q286R/M298Q/H373F, Q286R/M298Q/H373F, {Gla Swap FIX K[43]I}/ T128N/P129A/Q286R/M298Q /Q366N, {Gla Swap FIX K[43]I}/Q286R/M298Q/Q366N, Q286R/M298Q/Q366N, S52A/S60A/S222A/H257A/Q28R/M2986Q, T128N/P129A/S222A/H257A/Q286R/ M2986Q, S222A/H257A/Q286R/M298Q, {Gla Swap FIX/K[43]I}/T128N/P129A/Q286R/M298Q, Gla Swap FIX/S52A/S60A/ Q286R/M298Q, S52A/S60A/ Q286R/M298Q, {Gla Swap FIX/M[19]K}/ Q286R/M298Q, {Gla Swap FIX/Q[44]S}/ Q286R/M298Q, {Gla Swap FIX/K[43]I}/ Q286R/M298Q, {Gla Swap FIX/E[40]L}/ Q286R/M298Q, Gla Swap FIX /T128N/P129A/Q286R/M298Q and Q143R/M286Q/Gla swap FIX.

11. The modified FVII polypeptide of any of claims 1-10 that comprises the modifications Q286R/M298Q or T128N/P129A/A175S/Q286R/M298Q or T128N/P129A/A175S/Q286R/M298Q.

12. The modified Factor VII polypeptide of claim 1, comprising substitutions at amino acids corresponding to positions 128, 129, 286 and 298 in SEQ ID NO:3, wherein:

position 128 is substituted with asparagine (N), position 129 is substituted with alanine (A), position 286 is substituted with arginine (R) and position 298 is substituted with glutamine (Q),

the modified FVIIa polypeptide comprises a sequence of amino acids that has at least 90% or 95% sequence identity to the polypeptide of SEQ ID NO:3; and

the modified FVIIa polypeptide exhibits procoagulant activity.

13. The modified FVIIa polypeptide of claim 12, wherein the polypeptide is a FVIIa polypeptide.

14. The modified Factor VII polypeptide of claim 12 that is a two-chain activated Factor VII (FVIIa) polypeptide, consisting of the amino acid sequence of SEQ ID NO:280 cleaved between the arginine at position 152 and the isoleucine at position 153.

15. The modified Factor VII polypeptide of claim 12 that is a two-chain activated Factor VII (FVIIa) polypeptide, wherein the sequence of amino acids of the light chain of the modified FVIIa is at least 95% identical to the sequence of amino acid residues 1-152 of SEQ ID NO:280 and includes the amino acid replacements at positions 128 and 129.

16. The modified factor VII (FVII) polypeptide of claim 1 that consists of the sequence of amino acids set forth in SEQ ID NO:280.

17. The modified Factor VII polypeptide of claim 12 that is a two-chain activated Factor VII (FVIIa) polypeptide, consisting of the amino acid sequence of SEQ ID NO:280 cleaved between the arginine at position 152 and the isoleucine at position 153.

18. The modified Factor VII polypeptide of claim 12 that is a two-chain activated Factor VII (FVIIa) polypeptide, wherein the sequence of amino acids of the light chain of the modified FVIIa is at least 95% identical to the sequence of amino acid residues 1-152 of SEQ ID NO:280 and includes the amino acid replacements at positions 128 and 129.

19. The modified FVII polypeptide of any of claims 1-18 that comprises post-translational modifications.

20. The modified FVII polypeptide claim 19, wherein the post-translational modifications comprise glycosylation.

21. The modified FVII polypeptide of any of claims 1-15 and 18 that comprises modifications that introduce an additional glycosylation site.

22. The modified FVII polypeptide of claim 21, wherein the additional glycosylation site is introduced by the modification A122N/G124S.

23. The modified FVII polypeptide of any of claims 1-22, wherein the unmodified FVII polypeptide comprises a sequence of amino acids set forth in any of SEQ ID NOS: 1-3 or 18-74.

24. The modified FVII polypeptide of any of claims 1-15 and 18-23, comprising amino acid replacements Q286R/M298Q.

25. The modified FVII polypeptide of any of claims 1-24, comprising amino acid replacements T128N/P129A/Q286R/M298Q.

26. The modified FVII polypeptide of any of claims 1-25, comprising a sequence of amino acids set forth in any of SEQ ID NOS: 138-141, 154, 155, 157, 274-278, 280, 282, 286-288, 293-295, 297, 302-304, 306, 311-313, 317, 318, 321, 322, 324-326, 328, 337-342, 355-358, 360 or 364-371.

27. The modified FVII polypeptide of any of claims 1-16 that contains a heterologous Gla domain or a modification in the Gla domain.

28. The modified FVII polypeptide of claim 17, wherein the heterologous Gla domain has a sequence of amino acids set forth in any of SEQ ID NOS: 83-91, 93 and 94.

29. A modified FVII polypeptide of any of claims 1-18, comprising a serum albumin binding sequence in a FVII polypeptide, allelic and species variant thereof or active fragments thereof.

30. The modified FVII polypeptide of claim 19, wherein the serum albumin binding sequence has a sequence of amino acids set forth in any of SEQ ID NOS: 103-109, or a sufficient portion thereof to effect serum albumin binding.

31. The modified FVII polypeptide of claim 29 or claim 30, wherein the serum albumin binding sequence replaces a contiguous sequence of amino acid residues of the unmodified FVII polypeptide.

32. The modified FVII polypeptide of any of claims 29-31, comprising a modification selected from among S103S111delinsQRLMEDICLPRWGCLWEDDF, H115S126delinsQRLMEDICLPRWGCLWEDDF, T128P134delinsQRLMEDICLPRWGCLWEDDF, S103S111delinsIEDICLPRWGCLWE, H115S126delinsIEDICLPRWGCLWE, T128P134delinsIEDICLPRWGCLWE, S103S111delinsDICLPRWGCLWED, H115S126delinsDICLPRWGCLWED, T128P134delinsDICLPRWGCLWED, P406insIEDICLPRWGCLW, P406insGGGSIEDICLPRWGCLW, P406insDICLPRWGCLWED and P406insGGGSDICLPRWGCLWED.

33. A modified FVII polypeptide of any of claims 1-32, comprising a platelet integrin αIIbβ3 binding sequence.

34. The modified FVII polypeptide of claim 33, wherein the platelet integrin αIIbβ3 binding sequence has a sequence of amino acids set forth in any of SEQ ID NOS: 110-112, or a sufficient portion thereof to effect platelet integrin αIIbβ3 binding.

35. The modified FVII polypeptide of claim 33 or claim 34, wherein the platelet integrin αIIbβ3 binding sequence replaces a contiguous sequence of amino acid residues of the unmodified FVII polypeptide.

36. The modified FVII polypeptide of any of claims 33-35, comprising a modification selected from among S103S111delinsSFGRGDIRNV, H115S126delinsSFGRGDIRNV, T127P134delinsSFGRGDIRNV, P406insCSFGRGDIRNVC and P406insGGGSCSFGRGDIRNVC.

37. The modified FVII polypeptide of claim 36 further comprising an amino acid replacement at a position corresponding to a position G237V.

38. The modified FVII polypeptide of claim 37, comprising a modification selected from among S103S111delinsIEDICLPRWGCLWE/G237V, S103S111delinsDICLPRWGCLWED/G237V, H115S126delinsQRLMEDICLPRWGCLWEDDF/G237V, H115S126delinsIEDICLPRWGCLWE/G237V, H115S126delinsDICLPRWGCLWED/G237V, T128P134delinsQRLMEDICLPRWGCLWEDDF/G237V, T128P134delinsIEDICLPRWGCLWE/G237V, S103S111delinsQRLMEDICLPRWGCLWEDDF/G237V and T128P134delinsDICLPRWGCLWED/G237V.

39. The modified FVII polypeptide of any of claims 1-28, comprising 2, 3, 4, 5, 6, 7 or more modifications.

40. The modified FVII polypeptide of claim 27 or claim 28, wherein the heterologous Gla domain is selected from among a Gla domain in Factor IX (FIX), Factor X (FX), prothrombin, protein C, protein S, osteocalcin, matrix Gla protein, Growth-arrest-specific protein 6 (Gas6) and protein Z.

41. The modified FVII polypeptide of claim 28, wherein the native FVII Gla domain includes amino acids 1-45 in a FVII polypeptide having a sequence of amino acids set forth in SEQ ID NO:3, or in corresponding residues in a FVII polypeptide.

42. The modified FVII polypeptide of claim 28, wherein:

the heterologous Gla domain is a FIX Gla domain; and

the modification is an amino acid replacement at a position corresponding to a position selected from among positions 19, 40, 43 and 44 of the FIX Gla domain set forth in SEQ ID NO:83.

43. The modified FVII polypeptide of claim 42, wherein the modification is selected from among M19K, E40L, K43I and Q44S.

44. The modified FVII polypeptide of any of claims 1-43, comprising modifications selected from among {Gla Swap FIX/K43I}/Q286R/M298Q, {Gla Swap FIX/Q44S}/Q286R/M298Q, {Gla Swap FIX/M19K}/Q286R/M298Q, {Gla Swap FIX/M19K/E40L/K43I/Q44S}/Q286R/M298Q, Gla Swap FIX/T128N/P129A/S222A/Q286R, Gla Swap FIX/T128N/P129A/Q286R/M298Q, Gla Swap FIX/S52A/S60A/Q286R/M298Q, Gla Swap FIX/T239V/Q286R/M298Q, Gla Swap FIX/T239I/Q286R/M298Q, Gla Swap FIX/S222A/Q286R/M298Q, Gla Swap FIX/S222A/Q286R/M298Q/H373F, {Gla Swap FIX /K43I}/T128N/P129A/Q286R/M298Q and {Gla Swap FIX /K43I}/ T128N/P129A/Q286R/M298Q/Q366N.

45. The modified FVII polypeptide of any of claims 1-34, comprising one or more further amino acid modification(s) that increases resistance to antithrombin-III, increases binding and/or affinity to phospholipids, increases affinity for tissue factor, increases intrinsic activity, increases TF-dependent activity, increases coagulant activity, alters the conformation of the polypeptide to alter zymogenicity, increases catalytic or coagulant activity by shifting the equilibrium between highly active and less active FVIIa conformations in favor of the highly active conformations, increases resistance to proteases, decreases glycosylation, increases glycosylation, reduces immunogenicity, increases stability, and/or facilitates chemical group linkage.

46. The modified FVII polypeptide of any of claims 1-35, comprising one or more further amino acid modification(s) selected from among S279C/V302C, L280C/N301C, V281C/V302C, S282C/V299C, insertion of a tyrosine at position 4, F4S, F4T, P10Q, P10E, P10D, P10N, Q21N, R28F, R28E, I30C, I30D, I30E, K32D, K32Q, K32E, K32G, K32H, K32T, K32C, K32A, K32S, D33C, D33F, D33E, D33K, A34C, A34E, A34D, A34I, A34L, A34M, A34V, A34F, A34W, A34Y, R36D, R36E, T37C, T37D, T37E, K38C, K38E, K38T, K38D, K38L, K38G, K38A, K38S, K38N, K38H, L39E, L39Q, L39H, W41N, W41C, W41E, W41D, I42R, I42N, I42S, I42A, I42Q, I42N, I42S, I42A, I42Q, I42K, S43Q, S43N, Y44K, Y44C, Y44D, Y44E, S45C, S45D, S45E, D46C, A51N, S53N, G58N, G59S, G59T, K62E, K62R, K62D, K62N, K62Q, K62T, L65Q, L65S, L65N, F71D, F71Y, F71E, F71Q, F71N, P74S, P74A, A75E, A75D, E77A, E82Q, E82N, E82S, E82T T83K, N95S, N95T, G97S, G97T, Y101N, D104N, T106N, K109N, E116D, G117N, G124N, S126N, T128N, L141C, L141D, L141E, E142D, E142C, K143C, K143D, K143E, R144E, R144C, R144D, N145Y, N145G, N145F, N145M, N145S, N145I, N145L, N145T, N145V, N145P, N145K, N145H, N145Q, N145E, N145R, N145W, N145D, N145C, K157V, K157L, K157I, K157M, K157F, K157W, K157P, K157G, K157S, K157T, K157C, K157Y, K157N, K157E, K157R, K157H, K157D, K157Q, V158L, V158I, V158M, V158F, V158W, V158P, V158G, V158S, V158T, V158C, V158Y, V158N, V158E, V158R, V158K, V158H, V158D, V158Q, A175S, A175T, G179N, I186S, I186T, V188N, R202S, R202T, I205S, I205T, D212N, E220N, I230N, P231N, P236N, G237N, Q250C, V253N, E265N, T267N, E270N, A274M, A274L, A274K, A274R, A274D, A274V, A274I, A274F, A274W, A274P, A274G, A274T, A274C, A274Y, A274N, A274E, A274H, A274S, A274Q, F275H, R277N, F278S, F278A, F278N, F278Q, F278G, L280N, L288K, L288C, L288D, D289C, D289K, L288E, R290C, R290G,

R290A, R290S, R290T, R290K, R290D, R290E, G291E, G291D, G291C, G291N, G291K, A292C, A292K, A292D, A292E, T293K, E296V, E296L, E296I, E296M, E296F, E296W, E296P, E296G, E296S, E296T, E296C, E296Y, E296N, E296K, E296R, E296H, E296D, E296Q, M298Q, M298V, M298L, M298I, M298F, M298W, M298P, M298G, M298S, M298T, M298C, M298Y, M298N, M298K, M298R, M298H, M298E, M298D, P303S, P303T, R304Y, R304F, R304L, R304M, R304G, R304T, R304A, R304S, R304N, L305V, L305Y, L305I, L305F, L305A, L305M, L305W, L305P, L305G, L305S, L305T, L305C, L305N, L305E, L305K, L305R, L305H, L305D, L305Q, M306D, M306N, D309S, D309T, Q312N, Q313K, Q313D, Q313E, S314A, S314V, S314I, S314M, S314F, S314W, S314P, S314G, S314L, S314T, S314C, S314Y, S314N, S314E, S314K, S314R, S314H, S314D, S314Q, R315K, R315G, R315A, R315S, R315T, R315Q, R315C, R315D, R315E, K316D, K316C, K316E, V317C, V317K, V317D, V317E, G318N, N322Y, N322G, N322F, N322M, N322S, N322I, N322L, N322T, N322V, N322P, N322K, N322H, N322Q, N322E, N322R, N322W, N322C, G331N, Y332S, Y332A, Y332N, Y332Q, Y332G, D334G, D334E, D334A, D334V, D334I, D334M, D334F, D334W, D334P, D334L, D334T, D334C, D334Y, D334N, D334K, D334R, D334H, D334S, D334Q, S336G, S336E, S336A, S336V, S336I, S336M, S336F, S336W, S336P, S336L, S336T, S336C, S336Y, S336N, S336K, S336R, S336H, S336D, S336Q, K337L, K337V, K337I, K337M, K337F, K337W, K337P, K337G, K337S, K337T, K337C, K337Y, K337N, K337E, K337R, K337H, K337D, K337Q, K341E, K341Q, K341G, K341T, K341A, K341S, G342N, H348N, R353N, Y357N, I361N, F374P, F374A, F374V, F374I, F374L, F374M, F374W, F374G, F374S, F374T, F374C, F374Y, F374N, F374E, F374K, F374R, F374H, F374D, F374Q, V376N, R379N, L390C, L390K, L390D, L390E, M391D, M391C, M391K, M391N, M391E, R392C, R392D, R392E, S393D, S393C, S393K, S393E, E394K, P395K, E394C, P395D, P395C, P395E, R396K, R396C, R396D, R396E, P397D, P397K, P397C, P397E, G398K, G398C, G398D, G398E, V399C, V399D, V399K, V399E, L400K, L401K, L401C, L401D, L401E, R402D, R402C, R402K, R402E, A403K, A403C, A403D, A403E, P404E, P404D, P404C, P404K, F405K, P406C, K32N/A34S, K32N/A34T, F31N/D33S, F31N/D33T, I30N/K32S, I30N/K32T, A34N/R36S, A34N/R36T, K38N/F40S, K38N/F40T, T37N/L39S, T37N/L39T, R36N/K38S, R36N/K38T, L39N/W41S, L39N/W41T, F40N/I42S, F40N/I42T, I42N/Y44S, I42N/Y44T, Y44N/D46S, Y44N/D46T, D46N/D48S, D46N/D48T, G47N/Q49S, G47N/Q49T, K143N/ N145S, K143N/ N145T, E142N/R144S, E142N/R144T, L141N/K143S, L141N/K143T, I140N/E142S, I140N/E142T, R144N/A146S, R144N/A146T, A146N/K148S, A146N/K148T, S147N/P149S, S147N/P149T, R290N/A292S, R290N/A292T, D289N/G291S, D289N/G291T, L288N/R290S, L288N/R290T, L287N/D289S, L287N/D289T, A292N/A294S, A292N/A294T, T293N/L295S, T293N/L295T, R315N/V317S, R315N/V317T, S314N/ K316S, S314N/ K316T, Q313N/ R315S, Q313N/ R315T, K316N/G318S, K316N/G318T, V317N/D319S, V317N/D319T, K341N/ D343S, K341N/ D343T, S339N/K341S, S339N/K341T, D343N/G345S, D343N/G345T, R392N/E394S, R392N/E394T, L390N/ R392S, L390N/ R392T, K389N/M391S, K389N/M391T, S393N/P395S, S393N/P395T, E394N/R396S, E394N/R396T, P395N/P397S, P395N/P397T, R396N/G398S, R396N/G398T, P397N/V399S, P397N/V399T, G398N/L400S, G398N/L400T, V399N/L401S, V399N/L401T, L400N/R402S, L400N/R402T, L401N/A403S, L401N/A403T, R402N/P404S, R402N/P404T, A403N/F405S, A403N/F405T, P404N/P406S and P404N/P406T.

47. The modified FVII polypeptide of any of claims 1-46, comprising substitution of positions 300-322, 305-322, 300-312, or 305-312 with the corresponding amino acids from

trypsin, thrombin or FX, or substitution of positions 310-329, 311-322 or 233-329 with the corresponding amino acids from trypsin.

48. The modified FVII polypeptide of any of claims 1-47, wherein the unmodified FVII polypeptide has a sequence of amino acids set forth in SEQ ID NO:3.

49. The modified FVII polypeptide of any of claims 1-48 that is a mature polypeptide.

50. The modified FVII polypeptide of any of claims 1-49 that is a single-chain polypeptide or a two-chain polypeptide.

51. The modified FVII polypeptide of any of claims 1-40 that is and activated two-chain polypeptide.

52. A nucleic acid molecule, comprising a sequence of nucleotides encoding a modified FVII polypeptide of any of claims 1-51.

53. A vector, comprising the nucleic acid molecule of claim 52.

54. The vector of claim 53, wherein the vector is a prokaryotic vector, a viral vector, or an eukaryotic vector.

55. A cell, comprising the vector of claim 52 or claim 53.

56. The cell of claim 55, that is a eukaryotic cell.

57. The cell of claim 56, wherein the eukaryotic cell is a mammalian cell.

58. The cell of claim 57, wherein the mammalian cell is selected from among baby hamster kidney cells (BHK-21) or 293 cells or CHO cells.

59. A pharmaceutical composition, comprising a therapeutically effective concentration or amount of a modified FVII polypeptide of any of claims 1-51, or a nucleic acid molecule of claim 52 or a vector of claim 53 or claim 54 or a cell of any of claims 55-58, in a pharmaceutically acceptable vehicle.

60. The pharmaceutical composition of claim 59 that is formulated for single-dosage administration.

61. A modified FVII polypeptide of any of claims any of claims 1-52, for use in treating a disease or condition that is treated by administration of FVII or a pro-coagulant.

62. Use of a pharmaceutical composition of claim 59 or claim 61 in the preparation of a medicament for treatment of a disease or condition that is treated by administration of FVII or a pro-coagulant.

63. The modified FVII polypeptide of claim 61 or the use of claim 62, wherein the disease or condition is treated by administration of a zymogen or active form of FVII.

64. The modified FVII polypeptide of claim 61, or the use of claim 62 or claim 63, wherein treatment with the pharmaceutical composition ameliorates or alleviates the symptoms associated with the disease or condition.

65. The modified FVII polypeptide of any of claims 61, 63 and 64, or the use of any of claims 62-64, wherein the disease or condition to be treated is selected from among blood coagulation disorders, hematologic disorders, hemorrhagic disorders, hemophilias, factor VII deficiency, bleeding disorders, surgical bleeding, or bleeding resulting from trauma.

66. The modified FVII polypeptide or use of claim 65 wherein the disease or condition is hemophilia and the hemophilia is hemophilia A or hemophilia B or hemophilia C.

67. The modified FVII polypeptide or use of claim 65, wherein the hemophilia is congenital or is acquired.

68. The modified FVII polypeptide or use of claim 65, wherein the disease or condition is due to a bleeding complication due to surgery or trauma.